Pharmaceutical

Phosphoinositide 3-kinases (PI3Ks) were discovered in 1980, and since then drug developers have accelerated their research funds in order to find potential drug candidate for inhibiting PI3Ks for the treatment of cancers. Phosphatidylinositol 3-kinases (PI3Ks) are lipid kinases that act as intermediate signaling molecules in PI3K/AKT/mTOR signaling pathway. They are the key molecules that play central role in regulation of several cellular processes such as proliferation, adhesion, survival, and motility. Mutation in these genes causes dysregulation of PI3K, which causes resistance to conventional therapies including biologics, hormonal therapy, tyrosine kinase inhibi...